EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Designed endocytosis-inducing proteins degrade targets and amplify signals

Buwei Huang, Mohamad Abedi, Green Ahn, Brian Coventry, Isaac Sappington, Cong Tang, Rong Wang, Thomas Schlichthaerle, Jason Z Zhang, Yujia Wang, Inna Goreshnik, Ching Wen Chiu und 33 weitere

Nature · 20.02.2025 · 638 (8051) · 796-804

DOI: 10.1038/s41586-024-07948-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature, online erschienen am 25.09.2024. Verfasst von Buwei Huang und 44 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Washington, Seattle, WA, USA. Hauptthemen laut MEDLINE: Endocytosis, Proteolysis, Signal Transduction, Protein Engineering. Die Arbeit wurde bisher 161-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIAID NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras 1,2 (LYTACs) and cytokine receptor-targeting chimeras 3 (KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target protein binders leads to lysosomal trafficking and target degradation. As these receptors have different tissue distributions, the different EndoTags could enable targeting of degradation to different tissues. EndoTag fusion to a PD-L1 antibody considerably increases efficacy in a mouse tumour model compared to antibody alone. The modularity and genetic encodability of EndoTags enables AND gate control for higher-specificity targeted degradation, and the localized secretion of degraders from engineered cells. By promoting endocytosis, EndoTag fusion increases signalling through an engineered ligand–receptor system by nearly 100-fold. EndoTags have considerable therapeutic potential as targeted degradation inducers, signalling activators for endocytosis-dependent pathways, and cellular uptake inducers for targeted antibody–drug and antibody–RNA conjugates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndocytosisProteolysisSignal TransductionProtein EngineeringAnimalsMiceLysosomesHumansReceptors, TransferrinReceptor, IGF Type 2LigandsAdaptor Proteins, Vesicular TransportAsialoglycoprotein ReceptorFemaleRecombinant Fusion ProteinsSortilin

Substanzen

Receptors, TransferrinReceptor, IGF Type 2LigandsAdaptor Proteins, Vesicular TransportAsialoglycoprotein ReceptorRecombinant Fusion ProteinsSortilin

Autor:innen und Institutionen

  • Department of Biochemistry, University of Washington, Seattle, WA, USA.
  • Institute for Protein Design, University of Washington, Seattle, WA, USA.
  • Department of Bioengineering, University of Washington, Seattle, WA, USA.
  • Department of Chemistry, Stanford University, Stanford, CA, USA.
  • Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
  • Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.

Förderung

  • NIA NIH HHS
  • NIAID NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Huang, B., Abedi, M., Ahn, G., Coventry, B., Sappington, I., Tang, C., Wang, R., Schlichthaerle, T., Zhang, J. Z., Wang, Y., Goreshnik, I., Chiu, C. W., Chazin-Gray, A., Chan, S., Gerben, S., Murray, A., Wang, S., O'Neill, J., Yi, L., …, & Baker, D. (2025). Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature, 638(8051), 796-804. https://doi.org/10.1038/s41586-024-07948-2

Vancouver

Huang B, Abedi M, Ahn G, Coventry B, Sappington I, Tang C, et al. Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature. 2025;638(8051):796-804. doi:10.1038/s41586-024-07948-2

BibTeX
@article{Huang2025,
  author = {Huang, Buwei and Abedi, Mohamad and Ahn, Green and Coventry, Brian and Sappington, Isaac and Tang, Cong and Wang, Rong and Schlichthaerle, Thomas and Zhang, Jason Z and Wang, Yujia and Goreshnik, Inna and Chiu, Ching Wen and Chazin-Gray, Adam and Chan, Sidney and Gerben, Stacey and Murray, Analisa and Wang, Shunzhi and O'Neill, Jason and Yi, Li and Yeh, Ronald and Misquith, Ayesha and Wolf, Anitra and Tomasovic, Luke M and Piraner, Dan I and Duran Gonzalez, Maria J and Bennett, Nathaniel R and Venkatesh, Preetham and Ahlrichs, Maggie and Dobbins, Craig and Yang, Wei and Wang, Xinru and Sahtoe, Danny D and Vafeados, Dionne and Mout, Rubul and Shivaei, Shirin and Cao, Longxing and Carter, Lauren and Stewart, Lance and Spangler, Jamie B and Roybal, Kole T and Greisen, Per Jr and Li, Xiaochun and Bernardes, Gonçalo J L and Bertozzi, Carolyn R and Baker, David},
  title = {Designed endocytosis-inducing proteins degrade targets and amplify signals},
  journal = {Nature},
  year = {2025},
  volume = {638},
  number = {8051},
  pages = {796--804},
  doi = {10.1038/s41586-024-07948-2}
}
Kostenlos starten →